Role of Wilms’ tumor 1 in diagnosis and grading of astrocytomas

Authors

  • John Emmanuel Raju S Senior Resident, Department of Pathology, Government Medical College, Mahabubabad, Telangana, India https://orcid.org/0009-0002-5533-4561
  • Nalini B Senior Resident, Department of Pathology, Government Medical College, Mahabubabad, Telangana, India
  • Muderla Rajesh Assistant Professor, Department of Otorhinolaryngology, Government Medical College, Mahabubabad, Telangana, India
  • Bhavani Nagavelly Assistant Professor, Department of Pathology, Government Medical College, Mahabubabad, Telangana, India https://orcid.org/0009-0000-6738-1395

DOI:

https://doi.org/10.3126/ajms.v14i9.54531

Keywords:

Astrocytomas; Gliomas; Immunohistochemistry; Wilms’ tumor 1

Abstract

Background: Wilms’ tumor 1 (WT1) mutation has recently been detected in gliomas. Growing data indicate that WT1 mutation plays a causal role in gliomagenesis and is overexpressed in most glioblastomas. Emerging immunotherapy targeting WT1 has shown to be effective in resistant glioblastomas in clinical trials. WT1 expression and its potential utility in various grades of astrocytomas is still unclear and needs further elucidation. The evaluation of WT1 can be done by molecular or immunohistochemical methods. As immunohistochemistry is easier with wider routine use, immunoexpression of this biomarker was studied.

Aims and Objectives: This study aimed to evaluate WT1 immunoexpression across different histological grades of astrocytomas and differentiate low-grade astrocytomas from reactive astrogliosis.

Materials and Methods: This was an observational prospective study on 54 cases of astrocytomas.

Results: In the present study a total of 54 cases have been diagnosed as astrocytomas. Grade IV was the most common (31%) followed by grade II (44%). WT1 score correlated with histological tumor grades (P<0.001) with a higher score in a higher grade. It was also observed that different tumor grades depicted two distinct expression patterns. WT1 score and pattern were valuable in differentiating high- and low-grade astrocytomas.

Conclusion: This study supports the oncogenic role of WT1 in astrocytomas. WT1 was found to be valuable in distinguishing different grades of astrocytomas. The scoring and distinctive patterns of WT1 can aid in distinguishing high-grade and low-grade astrocytomas. However, one needs to be careful in pilocytic astrocytomas in which there is a mixed expression. WT1, therefore, appears to be an attractive immunohistochemistry (IHC) marker to be used concomitantly with other IHC markers in astrocytomas. In addition, the frequent expression of WT1 in astrocytomas supports its promising role in immunotherapy and its potential to guide patient selection for targeted immunotherapy.

Downloads

Download data is not yet available.
Abstract
44
PDF
59

Downloads

Published

2023-09-01

How to Cite

John Emmanuel Raju S, Nalini B, Rajesh, M., & Nagavelly, B. (2023). Role of Wilms’ tumor 1 in diagnosis and grading of astrocytomas. Asian Journal of Medical Sciences, 14(9), 187–192. https://doi.org/10.3126/ajms.v14i9.54531

Issue

Section

Original Articles